BXI-72

Research use only, not for human use.

BXI-72 (NSC334072, Hoechst 33342) is a potent, selective small molecule Bcl-XL inhibitor that targets the BH3 domain of Bcl-XL (Kd=0.9 nM).

BXI-72 (NSC334072, Hoechst 33342) is a potent, selective small molecule Bcl-XL inhibitor that targets the BH3 domain of Bcl-XL (Kd=0.9 nM); displays very low binding affinities with Bcl2 (Ki=283 nM), Mcl-1, Bcl-w and Bfl-1/A1 (Ki>1500 nM); potently suppresses lung cancer cell growth (H1299=0.49 uM, A549 IC50=0.68 uM), displays relatively selective cytotoxicity against lung cancer cells compared to normal human bronchial epithelial cells; caunses disruption of Bcl-XL/Bak or Bcl-XL/Bax interaction, oligomerization of Bak, and cytochrome c release from mitochondria in cells, BXI-72 exhibits more potent efficacy against human lung cancer than ABT-737 but less degree in platelet reduction in vivo.

——

——

NSC334072 | Bcl-XL inhibitor BXI-72 | Hoechst 33342

Angiogenesis

Bcl-2

Bcl-2

Other Indications

——

23491-52-3

489.01

C27H29ClN6O

>98% (HPLC)

In Vitro:?DMSO : 6.25 mg/mL (13.81 mM)

CN1CCN(C2=CC=C3C(N=C(C4=CC=C5C(N=C(C6=CC=C(OCC)C=C6)N5)=C4)N3)=C2)CC1.[H]Cl.[H]Cl.[H]Cl

2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-1H,1'H-2,5'-bibenzo[d]imidazole

(-20℃)

With Ice Pack

≥ 2 years